Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dazukibart Long-Term Extension Study in Idiopathic Inflammatory Myopathies
NCT06698796Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Jan 2025
- Primary completion
- Jul 2031
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 3 trial of dazukibart in idiopathic inflammatory myopathy (IIM), dermatomyositis (DM), polymyositis (PM), sponsored by Pfizer. Started Jan 2025; status: recruiting.
02
Drugs
dazukibart
03
Conditions
idiopathic inflammatory myopathy (IIM)dermatomyositis (DM)polymyositis (PM)
Beyond the preview
Go deeper on NCT06698796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06698796.